Michael Weber

Mar 20, 2024 | healio.com | Richard Smith |Michael Weber

You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Aprocitentan has been approved to treat hypertension in patients whose BP is uncontrolled. The drug is the first oral antihypertensive therapy working via a new pathway to be approved in nearly 40 years.

Apr 20, 2023 | thelancet.com | Markus Schlaich |Marc Bellet |Michael Weber |George Bakris

We thank Donald E Kohan and Hiddo J L Heerspink for their interest in the PRECISION study and their comments regarding the potential for fluid retention and heart failure associated with endothelin receptor antagonists. Indeed, as described in publications from the past few years,1Schlaich MP Bellet M Weber MA et al. Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial.